Animal experiment findings indicated that, compared with the model group, the DXTMG group effectively ameliorated inflammation and fibrosis in rat myocardial tissues, reduced LDH, cTn-I, and MDA levels (<i>P</i> < 0.05, <i>P</i> < 0.01), elevated SOD and GSH-PX levels (<i>P</i> < 0.05), and reduced the percentage of positive area for IL-6 and TNF-α (<i>P</i> < 0.05).<h4>Conclusion</h4>This study preliminarily suggests that DXTMG can modulate oxidative stress, inflammation response, and cardiomyocyte regulation, thereby mitigating the onset and progression of CHD. This evidence concerns the gene TNNI3 and coronary artery disorder.